Kaplan-Meier curves for PFS (A) and OS (B), according to MRD, in the IFM trial. Despite PFS and OS being prolonged in MRD-negative patients vs those who were MRD positive (adjusted hazard ratio [aHR], 0.30; 95% confidence interval [CI], 0.23-0.37; P < .001 and aHR, 0.34; 95% CI, 0.22-0.51; P < .001 respectively), progression occurred in ∼25% of MRD-negative patients at a median of 36 months follow-up, which, in turn, impaired OS.⁴³